Kirk Adams leaving longtime SEIU post

By Adam Rubenfire  |  September 03, 2015

Kirk Adams, the longtime healthcare chief for the Service Employees International Union, is leaving that role to join the Healthcare Education Project, a joint effort of 1199SEIU United Healthcare Workers East and the Greater New York Hospital Association.

What Medicare's value-based insurance test could mean for commercial plans

By Bob Herman  |  September 03, 2015

Supporters hope a new Medicare Advantage experiment offering lower out-of-pocket costs for high-value services and providers will become a template for health plans with sizable cost-sharing, which have become the standard offering from employers and insurers.

Acquisition of Covidien bumps Medtronic's first-quarter sales by 12%

By Steven Ross Johnson  |  September 03, 2015

Leading medical-device maker Medtronic on Thursday reported a 12% jump in revenue for the first quarter of its fiscal 2016 over the same period last year, driven by its purchase of surgical-device maker Covidien in January.

Sandoz launches sale of biosimilar Zarxio

By Steven Ross Johnson  |  September 03, 2015

The first biosimilar medication approved in the U.S. made its way to the market on Thursday, ushering in a new era of competition between such drugs and the original high-cost biologic therapies they emulate.

Bernd retiring as longtime CEO of Sentara Healthcare

By Adam Rubenfire  |  September 03, 2015

David Bernd, CEO of Norfolk, Va.-based Sentara Healthcare, is retiring next year. Howard Kern, Sentara's president and COO, assumes the role after Bernd's retirement, effective March 3, 2016.

Rules protecting human research subjects undergo overhaul

By Michael Sandler  |  September 03, 2015

HHS and 15 other agencies issued proposed updates to what's known as the Common Rule, created to protect human research subjects. The changes, coming ahead of a major White House precision-medicine initiative, include clearer consent rules for the reuse of stored blood or tissue.

Pfizer completes $15B acquisition of Hospira

By Associated Press  |  September 03, 2015

Drugmaker Pfizer says it has completed its roughly $15 billion purchase of the injectable-drug maker and infusion-device manufacturer Hospira, expanding its product offerings in a growing medical market.

Experimental blood disorder therapy shows promise in new studies

By Steven Ross Johnson  |  September 02, 2015

Two papers published online Wednesday in the New England Journal of Medicine show promising results in the treatment of two rare blood disorders using an experimental therapy developed by Menlo Park, Calif., biopharmaceutical firm Geron Corp.

Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.